select ad.sno,ad.journal,ad.title,ad.author_names,ad.abstract,ad.abstractlink,j.j_name,vi.* from articles_data ad left join journals j on j.journal=ad.journal left join vol_issues vi on vi.issue_id_en=ad.issue_id where ad.sno_en='6217' and ad.lang_id='5' and j.lang_id='5' and vi.lang_id='5'
ISSN: 2375-4508
Antonio Maselli, Martin Wilding, Sylvia del Grande, Stefania Riccio, Loredana Di Matteo and Brian Dale
Background:Patients at high risk of OHSS can experience difficulty in completing an IVF cycle with the administration of gonadotrophins. Here, we test a unique low-dose GnRH agonist protocol.
Methods: 0.1mg triptorlin acetate (decapeptyl) was administered to 18 patients at high risk of OHSS from day 5 of the menstrual cycle. Oocyte retrieval was performed 36 hours after the administration of 10000 IU human chorionic gonadotrophin, when follicles of 18-20mm were observed. Oocytes were fertilised in vitro and embryos transferred on day 3.
Results: Patients produced a mean of 4.1 ± 0.96 oocytes. After ICSI, a mean of 3.0 ± 0.84 embryos were transferred to the uterus. A total of 5 pregnancies were obtained from the 18 cycles. No patients were affected by OHSS.
Conclusions: Low-dose injections of GnRH analogues can cause multiple follicular development, mature oocytes and pregnancies in patients at risk of OHSS. This novel COH protocol appears safe and applicable as a valuable alternative to the natural cycle.